PEAK6 Investments’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

PEAK6 Investments’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-5,300	Closed	-$191K	–	4707
2023 Q2	$191K	Buy	+5,300	New	+$218K	﹤0.01%	2901
2023 Q1	–	Sell	-10,000	Closed	-$453K	–	5134
2022 Q4	$453K	Buy	+10,000	New	+$647K	﹤0.01%	2610
2022 Q3	–	Sell	-5,300	Closed	-$191K	–	6387
2022 Q2	$191K	Buy	+5,300	New	+$337K	﹤0.01%	4793

Other funds holding MRTX

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

PEAK6 Investments's MRTX Position: Q1 2024 in Review

PEAK6 Investments sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 20,003 shares — an estimated $1.18M sold.

PEAK6 Investments first reported a position in MRTX in Q1 2022 and held it in 7 quarters. The position peaked at $2.2M in Q2 2022. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

PEAK6 Investments reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
PEAK6 Investments sold 20,003 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $1.18M.
PEAK6 Investments first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2022 and held it in 7 quarters.
PEAK6 Investments's Mirati Therapeutics, Inc. Common Stock position peaked at $2.2M in Q2 2022.
2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on PEAK6 Investments's 13F filing for Q1 2024, filed 14 May 2024.